Standard Standard
Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon - A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. / Gliddon, A.E.; Dore, C.J.; Black, C.M. et al.
In:
Arthritis and Rheumatism, Vol. 56, No. 11, 01.11.2007, p. 3837-3846.
Research output: Contribution to journal › Article › peer-review
HarvardHarvard
Gliddon, AE, Dore, CJ, Black, CM, McHugh, N, Moots, R, Denton, CP, Herrick, A, Barnes, T, Camilleri, J, Chakravarty, K, Emery, P, Griffiths, B, Hopkinson, ND, Hickling, P, Lanyon, P, Laversuch, C, Lawson, T, Mallya, R, Nisar, M, Rhys-Dillon, C, Sheeran, T & Maddison, PJ 2007, '
Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon - A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.',
Arthritis and Rheumatism, vol. 56, no. 11, pp. 3837-3846.
https://doi.org/10.1002/art.22965
APA
Gliddon, A. E., Dore, C. J., Black, C. M., McHugh, N., Moots, R., Denton, C. P., Herrick, A., Barnes, T., Camilleri, J., Chakravarty, K., Emery, P., Griffiths, B., Hopkinson, N. D., Hickling, P., Lanyon, P., Laversuch, C., Lawson, T., Mallya, R., Nisar, M., ... Maddison, P. J. (2007).
Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon - A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis and Rheumatism,
56(11), 3837-3846.
https://doi.org/10.1002/art.22965
CBE
Gliddon AE, Dore CJ, Black CM, McHugh N, Moots R, Denton CP, Herrick A, Barnes T, Camilleri J, Chakravarty K, et al. 2007.
Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon - A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis and Rheumatism. 56(11):3837-3846.
https://doi.org/10.1002/art.22965
MLA
VancouverVancouver
Author
RIS
TY - JOUR
T1 - Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon - A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.
AU - Gliddon, A.E.
AU - Dore, C.J.
AU - Black, C.M.
AU - McHugh, N.
AU - Moots, R.
AU - Denton, C.P.
AU - Herrick, A.
AU - Barnes, T.
AU - Camilleri, J.
AU - Chakravarty, K.
AU - Emery, P.
AU - Griffiths, B.
AU - Hopkinson, N.D.
AU - Hickling, P.
AU - Lanyon, P.
AU - Laversuch, C.
AU - Lawson, T.
AU - Mallya, R.
AU - Nisar, M.
AU - Rhys-Dillon, C.
AU - Sheeran, T.
AU - Maddison, P.J.
PY - 2007/11/1
Y1 - 2007/11/1
KW - RHEUMATOLOGY
U2 - 10.1002/art.22965
DO - 10.1002/art.22965
M3 - Article
VL - 56
SP - 3837
EP - 3846
JO - Arthritis and Rheumatism
JF - Arthritis and Rheumatism
SN - 0004-3591
IS - 11
ER -